BioSpace News Archive

Eisai Co., Ltd. will present the efficacy, safety and biomarker findings from the company’s Phase 3 confirmatory Clarity AD clinical trial for lecanemab, an investigational anti-amyloid beta protofibril antibody for the potential treatment of mild cognitive impairment due to Alzheimer’s disease and mild AD with confirmed presence of amyloid pathology in the brain, at the 15th Clinical Trials on Alzheimer’s Disease conference.

Elpiscience Biopharmaceuticals, Inc. presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.

RVAC Medicines Pte. Ltd., a messenger RNA technology platform company incubated by CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, and the Agency for Science, Technology and Research announced the signing of a master research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore.